Eupraxia Pharmaceuticals’ (EPRX) Buy Rating Reaffirmed at HC Wainwright

HC Wainwright reissued their buy rating on shares of Eupraxia Pharmaceuticals (NASDAQ:EPRX) in a report issued on Friday,Benzinga reports. HC Wainwright currently has a $12.00 target price on the stock.

A number of other analysts have also recently weighed in on the stock. Lifesci Capital upgraded shares of Eupraxia Pharmaceuticals to a “strong-buy” rating in a report on Thursday, December 11th. Leede Financial upgraded Eupraxia Pharmaceuticals to a “strong-buy” rating in a report on Wednesday, October 29th. Wall Street Zen upgraded shares of Eupraxia Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Saturday, December 13th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Eupraxia Pharmaceuticals in a report on Wednesday, October 8th. Two analysts have rated the stock with a Strong Buy rating, four have given a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Buy” and an average price target of $11.67.

Eupraxia Pharmaceuticals Stock Down 5.5%

Shares of Eupraxia Pharmaceuticals stock opened at $8.12 on Friday. The business has a fifty day simple moving average of $6.58 and a 200-day simple moving average of $5.87. Eupraxia Pharmaceuticals has a fifty-two week low of $2.68 and a fifty-two week high of $8.74. The firm has a market cap of $292.00 million, a price-to-earnings ratio of -9.33 and a beta of 1.21.

Eupraxia Pharmaceuticals (NASDAQ:EPRX) last issued its quarterly earnings results on Tuesday, November 4th. The company reported ($0.19) EPS for the quarter, topping the consensus estimate of ($0.23) by $0.04. Analysts anticipate that Eupraxia Pharmaceuticals will post -0.67 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the stock. Vivo Capital LLC acquired a new stake in shares of Eupraxia Pharmaceuticals during the 3rd quarter valued at $7,965,000. Ally Bridge Group NY LLC acquired a new stake in Eupraxia Pharmaceuticals during the third quarter valued at $5,398,000. Velan Capital Investment Management LP purchased a new position in Eupraxia Pharmaceuticals in the third quarter valued at about $2,077,000. Alyeska Investment Group L.P. purchased a new position in Eupraxia Pharmaceuticals in the third quarter valued at about $1,475,000. Finally, Royal Bank of Canada increased its position in Eupraxia Pharmaceuticals by 21.1% in the 1st quarter. Royal Bank of Canada now owns 342,828 shares of the company’s stock worth $1,125,000 after purchasing an additional 59,683 shares during the last quarter.

Eupraxia Pharmaceuticals Company Profile

Eupraxia Pharmaceuticals, Inc (NASDAQ: EPRX) is a clinical-stage biotechnology company dedicated to the discovery and development of novel therapies for autoimmune and inflammatory diseases. The company’s core strategy centers on selectively expanding regulatory T cells (Tregs)—immune cells responsible for maintaining self-tolerance and limiting pathological inflammation—through its proprietary platform. Its lead therapeutic candidate is currently in Phase 1 clinical development in patients with systemic lupus erythematosus.

Based in Seattle, Washington, Eupraxia Pharmaceuticals conducts research and development activities across North America, collaborating with academic institutions and contract research organizations to advance its pipeline.